CMS Splits Coverage With Evidence Development Into Two Categories
Executive Summary
Medicare is offering added flexibility to pay for research-related expenses that arise in the clinical trials conducted for a Part B national coverage decision, under revisions to Medicare's coverage with evidence development policy, released July 12
You may also be interested in...
Are FDA And CMS Growing Apart? AEI’s Gottlieb Thinks So
While many pharmaceutical industry observers like to talk about the new ways in which FDA and CMS are working together and sharing information, Scott Gottlieb is offering a contrarian view on relations between the two agencies
Are FDA And CMS Growing Apart? AEI’s Gottlieb Thinks So
While many pharmaceutical industry observers like to talk about the new ways in which FDA and CMS are working together and sharing information, Scott Gottlieb is offering a contrarian view on relations between the two agencies
Will FDA/CMS Parallel Review Idea Make Headway This Time?
The possibility of simultaneous FDA and CMS evaluations of new health products is back in the front of agency officials' minds after a series of fits and starts over the past several years, says CMS Chief Medical Officer Barry Straube
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: